Amgen
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
Track Amgen in real time with a live news feed covering Amgen stock news, official press releases, company announcements, and an archive of historical Amgen news. ...more
Loading news...
Loading more...
10:01 AM | Monday | Jul 13, 2026
Sign in to download news snippet
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read full articleNo data available for this time period.
Change the time range to see results.
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read full article
On July 13, 2026, we present a detailed DCF analysis for Amgen Inc (AMGN), a company that has shown significant price performance over the past year with a 24.6
Read full article
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
Read full article
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
Read full article
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.
Read full article
Amgen (AMGN) closed the most recent trading day at $366.44, moving 2.06% from the previous trading session.
Read full article
Broadcom's Apple deal and AMD's self-driving ambitions powered the Nasdaq higher on Monday while the Dow spun its wheels.
Read full article
Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read full article
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.
Read full article
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
Read full article
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read full article
Cisco Systems is on a roll with its AI-powered platform. Coca-Cola saw volume growth in each of its marketing segments in the first quarter.
Read full article
The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN) new thyroid eye disease (TED) treatment, Lumvoa (veligrotug-vvze).
Read full article
No data available for this time period.
Change the time range to see results.